<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690206</url>
  </required_header>
  <id_info>
    <org_study_id>ZP1848-17111</org_study_id>
    <nct_id>NCT03690206</nct_id>
  </id_info>
  <brief_title>Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS</brief_title>
  <acronym>EASE SBS 1</acronym>
  <official_title>A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing
      parenteral support volume in patients with short bowel syndrome.

      Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to
      evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients
      with short bowel syndrome (SBS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">October 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weekly Parenteral Support (PS) volume</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in weekly PS volume from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response in PS volume</measure>
    <time_frame>20 and 24 weeks</time_frame>
    <description>Achieving at least 20 percent reduction in weekly PS volume from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days off PS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Achieving 1 or more days per week off PS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response in PS volume</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Reduction of at least 20 percent in PS volume from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaned off PS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Reduction in weekly PS volume of 100 percent (weaned off)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid composite effect</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in fluid composite effect from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy content</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in energy content of PS from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on PS</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in number of days on PS per week from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PS volume per week</measure>
    <time_frame>20 and 24 weeks</time_frame>
    <description>Achieving 40 percent in PS volume from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change scale (PGIC)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change PGIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>28 weeks</time_frame>
    <description>Incidence and type of Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in 12-Lead electrocardiogram (ECG)</measure>
    <time_frame>28 weeks</time_frame>
    <description>Number of patients with clinically significant changes in ECG will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Changes in blood pressure from baseline</measure>
    <time_frame>28 weeks</time_frame>
    <description>Changes in blood pressure will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Changes in body temperature from baseline</measure>
    <time_frame>28 weeks</time_frame>
    <description>Changes in body temperature will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Occurrence of anti-drug antibodies</measure>
    <time_frame>28 weeks</time_frame>
    <description>Occurrence of antibodies against glepaglutide</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Glepaglutide SC injections twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Glepaglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glepaglutide SC injections once weekly and placebo once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Glepaglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC injections twice weekly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glepaglutide</intervention_name>
    <description>Glucagon-Like Peptide-2 (GLP-2) analog</description>
    <arm_group_label>Glepaglutide SC injections once weekly and placebo once weekly</arm_group_label>
    <arm_group_label>Glepaglutide SC injections twice weekly</arm_group_label>
    <other_name>ZP1848</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for glepaglutide</description>
    <arm_group_label>Placebo SC injections twice weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activity.

          -  Diagnosis of SBS defined as remaining small bowel in continuity of estimated less than
             200 cm and considered stable with regard to PS need. No restorative surgery planned in
             the trial period.

          -  Requiring PS at least 3 days per week and maintains a stable PS volume for at least 2
             weeks.

          -  In case of remnant colon: documented colonoscopy which does not give rise to any
             safety concerns.

        Exclusion Criteria:

          -  More than 2 SBS-related or PS-related hospitalizations within 6 months prior to
             Screening. No SBS-related hospitalizations within 30 days prior to randomization.

          -  Poorly controlled inflammatory bowel disease that is moderately or severely active or
             fistula interfering with measurements or examinations required in the trial.

          -  Bowel obstruction.

          -  Known radiation enteritis or significant villous atrophy.

          -  Cardiac disease defined as: decompensated heart failure (New York Heart Association
             [NYHA] Class III-IV), unstable angina pectoris, and/or myocardial infarction within
             the last 6 months prior to Screening.

          -  Clinically significant abnormal ECG.

          -  Repeated systolic blood pressure measurements &gt; 180 mm Hg.

          -  Human immunodeficiency virus positive, acute liver disease, or unstable chronic liver
             disease.

          -  Any history of colon cancer. History of any other cancers unless disease-free state
             for at least 5 years.

          -  Estimated creatinine clearance &lt; 30 mL/min.

          -  Severe hepatic impairment.

          -  Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3
             months prior to Screening.

          -  Use of dipeptidyl peptidase (DPP)-4 inhibitors within 3 months prior to Screening.

          -  Unstable systemic immunosuppressive therapy within 3 months prior to Screening.

          -  Unstable biological therapy within 6 months prior to Screening.

          -  Females of childbearing potential, who are pregnant, breast-feeding, intend to become
             pregnant or are not using highly effective contraceptive methods.

          -  Previous exposure to glepaglutide.

          -  Current, or within 30 days prior to Screening, participation in another interventional
             clinical trial that includes administration of an active compound.

          -  Any condition or disease or circumstance that in the Investigator's opinion would put
             the patient at any undue risk, prevent completion of the trial, or interfere with the
             analysis of the trial results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Medical Director</last_name>
    <phone>+45 88 77 36 00</phone>
    <email>mag@zealandpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Trial Manager</last_name>
    <phone>+45 88 77 36 00</phone>
    <email>teg@zealandpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Transplant Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>68198-3285</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt - Med. Klinik I</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen - Innere Medizin I</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Radboud Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solumed</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Skawina sp. z o.o. im. Stanley Dudricka</name>
      <address>
        <city>Skawina</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLH Foundation NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of East Anglia</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Associate Medical Director</last_name>
      <email>mag@zealandpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

